Home Your basket
• Nasal cutaneous cryptococ...
   Price 5.50 €
• Cholesteatoma and osteora...
   Price 14.00 €
• The supracricoid laryngec...
   Price 10.50 €
• The clinical significance...
   Price 5.50 €
• Sinonasal malignant schwa...
   Price 5.50 €
• Laryngeal schwannoma: A c...
   Price 8.50 €
• Revascularized free scapu...
   Price 10.50 €
• Polymorphisms of the huma...
   Price 10.50 €
• Construction and validati...
   Price 10.50 €
• Extramuscular soft tissue...
   Price 8.50 €
• An important procedure in...
   Price 8.50 €
• Delayed labyrinthine fist...
   Price 10.50 €
• Learning curve in sialend...
   Price 10.50 €
• Bilateral facial nerve pa...
   Price 5.50 €
• Human skull development a...
   Price 10.50 €
• Role and importance of pH...
   Price 12.00 €
• Sinonasal malignant melan...
   Price 5.50 €
• Middle ear barotraumas du...
   Price 8.50 €
• Surgery of mucocele of th...
   Price 10.50 €
• A schwannoma of the hypog...
   Price 8.50 €
• Acute acoustic trauma, a ...
   Price 12.00 €
• IPSEN Foundation meeting:...
   Price 5.50 €
• Spontaneous cholesteatoma...
   Price 8.50 €
• Manual care in voice reha...
   Price 8.50 €
• Diagnostic value of fine-...
   Price 8.50 €
• The role of larynx kinest...
   Price 10.50 €
• Arachnoid granulations of...
   Price 10.50 €
• Characteristics of the ma...
   Price 12.50 €
• A simple assessment of qu...
   Price 10.50 €
• Evaluation of the handica...
   Price 10.50 €
• Comparison between extern...
   Price 10.50 €
• Aesthetic parotidectomy: ...
   Price 8.50 €
• Endobronchial lipomas and...
   Price 5.50 €
• Free novascularized bone ...
   Price 15.00 €
• Bone-Anchored Hearing Aid...
   Price 10.50 €
• A case of nasal NK/T cell...
   Price 5.50 €
• Postural control accordin...
   Price 10.50 €
• Correlation between laryn...
   Price 10.50 €
• The «intra-cordal polyp»:...
   Price 5.50 €
• Nasopharyngeal tuberculos...
   Price 5.50 €

Total Order 365.00 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Order
o Issue N# 3 - 2017 o

OTOLOGY

Observational study to assess the effect of Audistim® on the quality of life of patients presenting with chronic tinnitus


Authors : Frachet B, Portmann D, Allaert FA. (Paris, Bordeaux, Dijon)

Ref. : Rev Laryngol Otol Rhinol. 2017;138,3:79-85.

Article published in english
Downloadable PDF document english



Summary : Objectives: To evaluate the improvement of symptoms, quali­ty of life, psychological stress and sleep quality of patients suffering from chronic tinnitus after a 3 months intake of Audistim®. Methods: Observational study of Audistim® by ENT doctors in patients consulting them for chronic tinnitus. Evaluation criterion: THI quality of life score, PSQI sleep score, MSP-9 Stress score. Patients were examined at baseline and at 3 months. Results: 314 patients aged 54.1 ± 13.0 years and suffering from tinnitus since 5.8 ± 7.3 years were included in the study. At the end of the 3 months, patients’ quality of life chan­­ged from 44.6 ± 23.4 to 26.7 ± 18.7 corresponding to an impro­vement of 40.1% (< 0.0001), subjects’ stress from 38.5 ± 13.3 to 30.1 ± 10.8 to 3 months corresponding to an improve­ment of 21.8% (<0.0001) and sleep quality of 8.4 ± 4.5 to 5.4 ± 3.2 corresponding to an improvement of 35.7%. Quality of life improvement was significantly correlated with stress impro­vement (r: 0.77 (p< 0.0001) and sleep (r: 0.70 (p< 0.0001). Tinnitus were improved in 70.0% of patients according to doc­tors, and in 69% of them according to the patients themselves. 2.8% of patients experienced adverse events, essentially diges­tive, none of which was judged by doctors as imputable to the intake of Audistim®. Conclusion: The original composition of Audistim® combining several active ingredients used to control tinnitus gives rise to clear improvements in the quality of life, stress and sleep of the patients experiencing tinnitus and provides them satisfaction without the risk of adverse events.


Price : 14.00 €      order
|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE